The document lists the top 10 licensing deals in 2008, providing the ranking, company, deal type, product, deal partner/product, deal value in millions of dollars, and deal date. GlaxoSmithKline had the highest valued deal of $3 billion in July 2008 for the in-licensing of Almorexant from Actelion. Other notable deals included Genzyme in-licensing Mipomersen from Isis Pharmaceuticals for $1.9 billion and Roche in-licensing R7334 from ThromboGenics for $750 million.

1. Rank Company Deal Type Product
Deal Partner/ Product
Source
Deal
Value($m)
Deal
Date
1 GlaxoSmithKline In-licensed Almorexant (ACT-078573) Actelion 3,009 Jul-08
2 Genzyme In-licensed Mipomersen Isis Pharmaceuticals 1,900 Jan-08
3 Roche In-licensed R7334 ThromboGenics 750 Jun-08
4 Astellas Pharma In-licensed CTS-21166 CoMentis 744 Apr-08
5 Pfizer In-licensed Dimebon Medivation 725 Oct-08
6 Bristol-Myers Squibb In-licensed Elotuzumab PDL BioPharma 710 Aug-08
7 Merck KGaA In-licensed Asonep Lpath 696 Oct-08
8
GlaxoSmithKline In-licensed
Efflux Pump Inhibitors
Research Project Mpex Pharmaceuticals
655 Jun-08
9 GlaxoSmithKline In-licensed Retigabine Valeant Pharmaceuticals 634 Aug-08
10 Nycomed In-licensed Veltuzumab (IMMU-106) Immunomedics 591 Jul
Prepared By: ManasRanjanRout
Pharmaceutical & Healthcare Professional
New Delhi
Email: manasranjanrout4cv@gmail.com